Principal Financial Group Inc Catalyst Pharmaceuticals, Inc. Transaction History

Principal Financial Group Inc

$1.66 Trillion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$15.19 - $21.35 $961,116 - $1.35 Million	-63,273 Reduced 9.9%	575,953 $11.4 Million
Q2 2024 Jul 29, 2024	SELL	$14.68 - $16.92 $149,941 - $172,820	-10,214 Reduced 1.57%	639,226 $9.9 Million
Q1 2024 Apr 29, 2024	BUY	$13.18 - $17.11 $937,532 - $1.22 Million	71,133 Added 12.3%	649,440 $10.4 Million
Q4 2023 Feb 07, 2024	BUY	$11.78 - $17.29 $5,630 - $8,264	478 Added 0.08%	578,307 $9.72 Million
Q3 2023 Nov 02, 2023	SELL	$11.69 - $15.02 $36,952 - $47,478	-3,161 Reduced 0.54%	577,829 $6.75 Million
Q2 2023 Aug 07, 2023	SELL	$11.5 - $18.08 $373,853 - $587,762	-32,509 Reduced 5.3%	580,990 $7.81 Million
Q1 2023 May 09, 2023	SELL	$14.34 - $21.05 $265,677 - $389,993	-18,527 Reduced 2.93%	613,499 $10.2 Million
Q4 2022 Feb 09, 2023	BUY	$12.25 - $19.5 $292,272 - $465,250	23,859 Added 3.92%	632,026 $11.8 Million
Q3 2022 Nov 09, 2022	BUY	$7.06 - $15.52 $3.78 Million - $8.31 Million	535,171 Added 733.15%	608,167 $7.8 Million
Q2 2022 Aug 10, 2022	SELL	$6.23 - $8.57 $36,183 - $49,774	-5,808 Reduced 7.37%	72,996 $512,000
Q1 2022 May 09, 2022	SELL	$5.31 - $8.31 $211,741 - $331,369	-39,876 Reduced 33.6%	78,804 $653,000
Q4 2021 Feb 09, 2022	BUY	$5.21 - $7.45 $618,322 - $884,166	118,680 New	118,680 $803,000
Q3 2021 Nov 09, 2021	SELL	$4.85 - $6.04 $54,344 - $67,678	-11,205 Closed	0 $0
Q2 2021 Aug 10, 2021	SELL	$4.29 - $6.05 $40,737 - $57,450	-9,496 Reduced 45.87%	11,205 $64,000
Q1 2021 May 10, 2021	SELL	$3.45 - $4.69 $18,564 - $25,236	-5,381 Reduced 20.63%	20,701 $95,000
Q4 2020 Feb 08, 2021	SELL	$2.97 - $3.83 $30,014 - $38,705	-10,106 Reduced 27.93%	26,082 $87,000
Q3 2020 Nov 06, 2020	SELL	$2.97 - $5.08 $5,494 - $9,398	-1,850 Reduced 4.86%	36,188 $107,000
Q2 2020 Aug 05, 2020	BUY	$3.48 - $5.05 $36,599 - $53,110	10,517 Added 38.21%	38,038 $176,000
Q1 2020 May 12, 2020	SELL	$2.61 - $5.21 $1,479 - $2,954	-567 Reduced 2.02%	27,521 $106,000
Q4 2019 Feb 05, 2020	SELL	$3.67 - $5.7 $6,286 - $9,764	-1,713 Reduced 5.75%	28,088 $105,000
Q3 2019 Nov 13, 2019	BUY	$3.89 - $7.43 $8,184 - $15,632	2,104 Added 7.6%	29,801 $158,000
Q2 2019 Aug 12, 2019	BUY	$2.7 - $6.11 $39,690 - $89,817	14,700 Added 113.1%	27,697 $107,000
Q1 2019 May 10, 2019	SELL	$2.11 - $5.33 $3,726 - $9,412	-1,766 Reduced 11.96%	12,997 $66,000
Q4 2018 Feb 14, 2019	SELL	$1.92 - $3.62 $6,940 - $13,086	-3,615 Reduced 19.67%	14,763 $28,000
Q3 2018 Nov 14, 2018	BUY	$2.81 - $3.78 $11,214 - $15,085	3,991 Added 27.74%	18,378 $69,000
Q2 2018 Aug 13, 2018	BUY	$2.26 - $3.84 $32,514 - $55,246	14,387 New	14,387 $0
Q1 2018 May 14, 2018	SELL	$2.39 - $4.01 $26,815 - $44,992	-11,220 Closed	0 $0
Q3 2017 Nov 02, 2017	BUY	$2.4 - $2.94 $26,928 - $32,986	11,220	11,220 $28,000

Others Institutions Holding CPRX

# of Institutions

328

Shares Held

94.2M

Call Options Held

19.1K

Put Options Held

51.1K

Black Rock Inc. New York, NY

18.7M
Shares

$428 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

8.04M
Shares

$184 Million
0.0% of portfolio
Deerfield Management Company, L.P. (Series C) New York, NY

6.23M
Shares

$142 Million
2.3% of portfolio
State Street Corp Boston, MA

5.69M
Shares

$130 Million
0.0% of portfolio
Dimensional Fund Advisors LP Austin, TX

3.02M
Shares

$69 Million
0.01% of portfolio

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.35B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account